answer text |
<p>The Secretary of State and the Department have had no specific discussions with
Servier about making Vorasidenib available to clinically suitable brain tumour patients
in the United Kingdom under the Early Access to Medicines Scheme (EAMS).</p><p>The
Medicines and Healthcare Products Regulatory Agency (MHRA) has also not had any specific
discussions with the Secretary of State regarding Vorasidenib. The MHRA has not issued
a scientific opinion for Vorasidenib under EAMS but should an application for this
be received, the MHRA will consider this accordingly.</p>
|
|